BCG in Combination With Durvalumab in Adult BCG-naïve, High-risk NMIBC Participants

Summary

The purpose of this study is to assess the safety, tolerability, and efficacy profile of durvalumab + BCG (induction and maintenance) combination therapy in adult United States participants with a histologically confirmed diagnosis of high-risk non-muscle-invasive bladder cancer (NMIBC), who have received no prior systemic therapy for NMIBC, and who are BCG-naïve.

Timeline

Start

2023-08-11

Primary completion

2025-06-16

Completion

2027-03-31

Drugs

Indications